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Sativex® is an oromucosal spray indicated for the treatment of moderate to severe spasticity 
in multiple sclerosis and is also an effective analgesic for advanced cancer patients. Sativex 
contains Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in an approximately 1:1 
ratio. The increasing prevalence of medicinal cannabis products highlights the importance of 
reliable bioanalysis and re-evaluation of the interpretation of positive test results for THC, as 
legal implications may arise in workplace, roadside and sports drug testing situations. This 
article summarises published research on the bioanalysis of THC and CBD, with particular 
focus on Sativex. Common screening and confirmatory testing of blood, urine, oral fluid and 
hair samples are outlined. Correlations between matrices and current analytical pitfalls are 
also addressed.  
Background 
Cannabis has been used for its psychoactive effects and medicinal properties since at least 
the sixth century BC. Research into cannabis expanded after the mid-1960s as recreational 
use of the drug erupted in the United States (US) and Europe [1]. Following the structural 
elucidation of Δ9-tetrahydrocannabinol (THC) in 1964 and its synthesis in 1967 by 
Mechoulam et al. [1], it became widely researched as the only major psychoactive constituent 
of cannabis. Mechoulam et al. also elucidated the structure of cannabidiol (CBD), another 
major cannabinoid found in cannabis, in 1963. However, it was initially neglected in 
research due to its lack of psychoactivity [1]. More recently, CBD has been found to have a 
number of therapeutic pharmacological effects [2].  
Cannabinoid content varies considerably between Cannabis sativa L. plant varieties. Many 
strains have been developed to be rich in THC for increased potency. Even within strains 
there is great variability in cannabinoid ratios. There is little data available on the CBD 
content in cannabis products, however as THC content has increased over the years, CBD 
levels have remained low. In the US, THC content in cannabis rose from <3.4% in 1993 to 
8.8% in 2008, while CBD content remained low at 0.4% in 2008 [3]. In Australia, an average 
THC and CBD content in cannabis samples obtained from recreational users were found to 
be 14.88% and 0.14%, respectively [4]. 
THC affects the central nervous system (CNS) by slowing down the messages travelling 
between the brain and the body through its actions at presynaptic receptors, inhibiting the 
release of neurotransmitters [5]. The psychotropic effects associated with cannabis use have 
been correlated to the actions of THC as a partial agonist to cannabinoid CB1 receptors in 
the CNS and peripheral CB2 receptors [6]. Cannabis has both hallucinogenic and depressant 
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properties resulting in CNS effects such as a sense of relaxation, loss of inhibition, impaired 
coordination, reduced concentration, hallucinations, anxiety, reduced brain function and 
paranoia, most of which are attributed to the actions of THC [7]. CBD in particular, has 
antipsychotic and anxiolytic CNS effects [2]. CBD has a weak affinity for the CB1 and CB2 
receptors, but has been shown to act as an antagonist of CB1 and CB2 agonists, resulting in 
some observed modulation of the effects of THC [8]. CBD has also been found to have 
antioxidant, anti-inflammatory and neuroprotective properties [2]. CBD itself has thus been 
investigated for its potential clinical use in the treatment of psychosis, epilepsy, anxiety and 
sleep disorders, diabetes, hypertension, cerebral and myocardial ischemia, depression, 
obesity, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), 
Alzheimer’s, Parkinson’s and Huntington’s diseases [2, 8, 9]. 
Sativex® (nabiximols) is an oromucosal spray containing THC and CBD in an approximately 
1:1 ratio. It is indicated for the treatment of moderate to severe spasticity in multiple 
sclerosis where patients have not adequately responded to existing treatments [10, 11] and is 
also effective as an analgesic for advanced cancer patients [6, 12, 13]. Pre-clinical trials of 1:1 
formulations of THC and CBD and clinical trials of Sativex have also been carried out to 
evaluate potential in treating pain caused by rheumatoid arthritis [14], as a neuroprotective 
agent in ALS [15] and Huntington’s disease [16], and in minimising withdrawal symptoms 
in chronic cannabis smokers [17].  
There is a large body of research covering the bioanalysis of THC and its metabolites due to 
the widespread illicit use of cannabis. Clinical, forensic, and workplace drug testing of 
cannabis generally target THC and its major metabolites, 11-hydroxy-Δ9-
tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-
COOH) in blood, urine, oral fluid and hair to monitor cannabis use. Bioanalysis of CBD has 
also been investigated, albeit to a lesser extent. The use of cannabinoids in medicinal 
cannabis products increases the importance of reliable bioanalysis and re-evaluation of the 
interpretation of positive test results for THC, as legal implications may arise in workplace, 
roadside, and sports drug testing situations. 
This review summarises the recent research published on the bioanalysis of THC and CBD, 
with particular focus on Sativex, in blood, urine, oral fluid and hair. Available screening 
tests as well as confirmatory testing techniques using gas chromatography–mass 
spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) are 
outlined. Correlations between matrices and analytical pitfalls are also addressed. 
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Formulation and synthesis of Sativex 
Sativex is the lead product of manufacturer GW Pharmaceuticals. The oromucosal spray is 
available in a 10 mL vial containing 27 mg/mL THC and 25 mg/mL CBD dissolved in 
ethanol, propylene glycol and peppermint oil [10]. The spray delivers approximately 100 µL 
per actuation containing 2.7 mg THC, 2.5 mg CBD, and up to 0.04 g ethanol [10]. The process 
of manufacturing Sativex at GW Pharmaceuticals was reviewed by Potter [18] and is briefly 
summarised here. 
GW Pharmaceuticals grows cannabis plants in pots in a highly regulated glasshouse 
environment. Lighting and temperature are strictly controlled to minimise variability 
between crops and to enhance yield. Sativex is produced from two separate cannabis 
extracts. Homozygous plants that produce mainly either THC or CBD are grown, and the 
resulting extracts are mixed to provide a standardised medicine containing THC and CBD at 
an approximately 1:1 ratio. The use of two homozygous plants gives a more reliable ratio of 
THC: CBD than growing heterozygous plants that produce both THC and CBD, due to a 
large variability in ratios being dependent on a multitude of environmental factors. 
Additionally, cuttings of the highest performing plants are taken for propagation as this 
leads to more uniform plants than if the seedlings of those plants were used. 
The majority of cannabinoids are produced in the female flowers of the cannabis plant, 
therefore GW Pharmaceuticals enhance cannabinoid yields in their crops by growing female 
plants in the absence of pollen which extends the flowering period. Cannabis naturally 
begins to flower in autumn, when night length begins to increase. This is simulated in the 
glasshouse using electric lighting to create 12 hr days and 12 hr nights when appropriate. 
Sativex (THC genotype) plants are typically harvested after eight weeks in short day length. 
The dried plant material, including the foliage and flora, is uniformly heated to 
decarboxylate the precursors THC-A and CBD-A to THC and CBD. The plant material is 
then immersed in liquid carbon dioxide at a high pressure to dissolve the ingredients, which 
are then separated and purified to create the extracts. Finally, the extracts from the THC and 
CBD plants are mixed with the other excipients, ethanol, propylene glycol and peppermint 
oil. 
Disposition and metabolism 
When cannabis is smoked, THC is quickly absorbed and can be measured in the plasma 
seconds after beginning smoking [19]. Plasma protein binding of THC is high (94–99%) [20]. 
The high lipophilicity of cannabinoids results in rapid redistribution into the fatty tissues 
where they can be stored for weeks and slowly excreted at low concentrations [21]. CBD has 
similar pharmacokinetic properties as THC. Both THC and CBD are rapidly converted to 
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their metabolites with a similar plasma clearance [21]. Median plasma maximum 
concentrations of THC and CBD were found to be 76 and 2.0 ng/mL, respectively, at 15 min 
after beginning smoking a single cigarette containing 54 mg of THC and 2.0 mg of CBD [22]. 
CBD was not detectable after 1 hr whereas THC was detected for at least 2 hr with a 30% 
detection rate in plasma after 22 hr [22]. Mean plasma levels of CBD were 5.9–11.2 ng/mL 
during daily oral dosage of 10 mg/kg CBD via capsules [23]. CBD was detectable for a week 
at 1.5 ng/mL after dosage ceased [23], a much longer window of detection than that 
observed following smoking. Following smoking of one cannabis cigarette, concentration of 
THC and its metabolites were found to be higher in frequent smokers and detectable for 
longer, when compared with occasional smokers, however, CBD levels did not vary greatly 
[24]. 
THC and CBD administered via an oromucosal spray, result in significantly lower 
cannabinoid blood concentrations due to the relatively slower adsorption via this route and 
the subsequent rapid redistribution into the fatty tissues [25]. Mean peak plasma 
concentrations were found to be reached an average of 1 hr after administration of Sativex 
and increased with increasing multiple doses, though there was no evidence of 
accumulation with multiple doses [25]. Concentrations of THC and CBD have been found to 
reach a maximum ~2.5 hr later in subjects who had been fed versus those who had fasted 
[26]. THC bioavailability is low at 6% when administered orally through capsules compared 
with inhaling (up to 27%) due to extensive first-pass metabolism [27]. The bioavailability of 
THC from capsules containing cannabis extract with 10 mg THC and 5.4 mg CBD was 3–
14% [28]. The bioavailability of THC from administered Sativex was 13.1% and 11.0% for 5 
and 15 mg doses, respectively [27]. When CBD was smoked, bioavailability ranged from 
11% to 45% with an average of 31% across five subjects [21]. CBD was observed to have a 
lower bioavailability than THC after administration of Sativex [25].  
Phase I metabolism of THC and CBD occurs primarily in the liver with the aid of 
cytochrome P450 enzymes. THC is hydroxylated at the C11 position to the active metabolite 
11-OH-THC (Figure 1a). This is further oxidised to the inactive THC-COOH (Figure 1b) and 
a number of other minor metabolites [20, 29]. CBD is extensively metabolised and similarly 
undergoes hepatic first-pass metabolism to 7-OH-CBD which is further oxidised to CBD-7-
oic acid (Figure 2a-b) [30]. A number of additional hydroxylated and oxidised minor 
metabolites of THC [20] and CBD [31] are also formed, however the aforementioned major 
phase I metabolites are the most important from a bioanalysis point of view. Phase II 
metabolism of the cannabinoids by UDP-glucuronosyltransferases [32] yields more 
hydrophilic metabolites including THC-glucuronide (THC-glu) and THC-COOH-
glucuronide (THC-COOH-glu) from THC (Figure 1c-d) [24, 33] and CBD-glucuronide (CBD-
glu) and 7-OH-CBD-glucuronide (7-OH-CBD-glu) from CBD (Figure 2c-d) [34, 35]. The 
major excretion route of THC is via the faeces as the conjugated 11-OH-THC and THC-
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COOH. THC-COOH and other carboxylic acid metabolites are also excreted in the urine in 
both free and conjugated forms [20]. Plasma concentrations of THC-COOH increase slowly 
over the first hour following the commencement of smoking and levels plateau by 2–4 hours 
[24]. A high percentage of free-CBD is excreted in the faeces [36]. A significant portion of 









Figure 1: Major metabolites of THC. Phase I metabolites 11-OH-THC (a) and THC-COOH (b); Phase II metabolites THC-glu 










Figure 2: Major metabolites of CBD. Phase I metabolites 7-OH-CBD (a) and CBD-7-oic acid (b); Phase II metabolites CBD-
glu (c) and 7-OH-CBD-glu (d). 
Nadulski et al. [28] found evidence that CBD partially inhibits the CYP 2C catalysed 
hydrolysis of THC to 11-OH-THC, although the effect was relatively small. The modulating 
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effects of CBD on THC were determined to be unlikely due to pharmacokinetic interactions 
at low, therapeutic doses as the bioavailability of THC did not significantly change when 
CBD was present [27, 28]. 
Methods of bioanalysis 
Most commonly, cannabis testing is performed using urine, plasma or whole blood, or oral 
fluid. Other matrices such as hair and sweat have also been regarded as useful for drug 
analysis in some circumstances. Target analytes vary between matrices, but generally 
include the major cannabinoids, THC, CBD and cannabinol (CBN), and THC metabolites, 
11-OH-THC, THC-COOH and THC-COOH-glu and THC-glu. On-site immunoassay 
screening tests for cannabis are widely available for urine and oral fluid testing, though 
none target CBD. Urine screening tests mainly target THC-COOH, while oral fluid tests 
target the parent THC. Laboratory-based immunoassay screening techniques include 
enzyme-multiplied immunoassay technique (EMIT), enzyme-linked immunosorbent assay 
(ELISA), cloned enzyme donor immunoassay (CEDIA) and fluorescence polarisation 
immunoassay (FPIA), which mainly target THC-COOH in urine and blood. Confirmatory 
laboratory testing focusses heavily on mass spectrometric techniques. GC–MS is the most 
widespread, although LC–MS/MS is catching up as detection limits have recently matched 
those of GC–MS and less samples preparation is required due to the lack of a derivatising 
step necessary for GC–MS. GC–MS has continued to be prominent as it evolves into more 
sensitive GC–MS/MS and 2D–GC–MS forms. Due to the isobaric relationship and structural 
similarities between THC and CBD, they produce a similar mass fragmentation pattern and 
therefore need to be separated chromatographically, or subjected to a derivatisation that 
yields distinguishable products in the mass spectrum [37, 38]. 
Blood 
Both plasma and whole blood matrices can be analysed to determine drug use. These 
matrices are most useful for post-accident and post-mortem analyses as samples are 
collected off-site at a hospital or morgue, where the necessary specialised personnel and 
facilities are readily available. THC has a plasma half-life of about 2 hours; after which it is 
converted into its metabolites, therefore the detection of THC rather than THC-COOH in 
plasma, is a useful indicator of recent use [39]. However, THC is present in lower 
concentrations, requiring sensitive analysis techniques. Karschner et al. [27] found average 
peak plasma CBD concentrations of 1.6 and 6.7 ng/mL, 3.7 and 4.0 hr after low (5.4 mg THC; 
5.0 mg CBD) and high (16.2 mg THC; 15.0 mg CBD) Sativex doses, respectively; THC gave 
average peak plasma concentrations of 5.1 and 15.3 ng/ml at 3.3 and 4.0 hr after low and 
high Sativex doses. THC-COOH was present in plasma in much higher concentrations at 
108.0 and 126.6 ng/ml, 4.4 and 4.8 hr following dosage [27]. Subjects given oral doses of 10 
mg THC and 5.4 mg CBD via capsules had peak plasma concentrations of 4.05 ng/mL THC 
and 0.95 ng/mL CBD 1 hr following dosage [38]. 
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Elimination of cannabinoids is variable between individuals and metabolites can be detected 
in the blood of chronic daily smokers during a month of sustained abstinence [40]. There is 
also some evidence that fat-stored THC can be redistributed into the blood of chronic users 
following extensive exercise [41]. These effects can have implications for the interpretation of 
single positive test results. 
Screening tests 
Laboratory-based blood screening for drugs is well established; the most common methods 
of screening are immunoassay-type tests such as ELISA, and LC–MS. LC–MS/MS techniques 
have been utilised to rapidly screen for multiple drugs at once. These generally target the 
major metabolite of each drug, so THC-COOH is generally the target compound for 
cannabis. ELISA kits have been used to detect THC-COOH in blood with a cut-off of 20 
ng/mL [42]. Neither ELISA nor LC–MS screening methods target CBD. 
 
Confirmatory tests 
Nadulski et al. [38] quantified cannabinoids and THC metabolites in plasma by GC–MS. 
Derivatisation was found to be essential for the detection of 11-OH-THC and THC-COOH, 
and improved chromatography for THC, CBD and CBN. Various derivatising agents were 
evaluated, and N-O-bistrifluoroacetamide (BSTFA) was found to be more suitable than 
methylating and other silylating agents based on derivatising efficiency, stability and 
availability. Quantification limits of the trimethylsilyl (TMS) derivatives monitored in 
selected ion monitoring (SIM) mode following auto-SPE were 0.080 ng/mL (THC), 0.95 
ng/mL (CBD), 3.9 ng/mL (CBN), 0.5 ng/mL (11-OH-THC) and 0.88 ng/mL (THC-COOH). 
Stott et al. [26] also used GC–MS to detect the TMS derivatives of THC, CBD and 11-OH-
THC, and achieved an LOQ of 0.1 ng/mL for all analytes. Karschner et al. [43] validated a 
2D–GC–MS method to quantify THC, CBD, 11-OH-THC and THC-COOH in plasma. THC, 
CBD and THC-COOH were quantifiable down to 0.25 ng/mL and 11-OH-THC was 
quantifiable at 0.125 ng/mL from 1 mL plasma samples extracted by SPE and derivatised 
with BSTFA.  
Jagadeo et al. [44] achieved quantification limits of 2 ng/mL for THC and 3 ng/mL for CBD, 
11-OH-THC and THC-COOH in 1 mL samples of whole blood using a method involving 
protein precipitation with acetonitrile and LC–MS/MS with online SPE. Whole blood 
analysis of cannabinoids and THC metabolites including glucuronides was achieved by 
Schwope et al. [45] using LC–MS/MS following protein precipitation and an SPE method 
modified to reduce build-up of phospholipids that can cause ion suppression. The LOQ of 
THC, CBD, CBN, 11-OH-THC and THC-COOH was 1.0 ng/mL, THC-glu had an LOQ of 0.5 
ng/mL and THC-COOH-glu had an LOQ of 5.0 ng/mL [45]. THC-glu and THC-COOH-glu 
were quantified in a real sample at 0.6 ng/mL and 96 ng/mL, respectively [45].  
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Urine 
Routine urine testing involves the detection of cannabis metabolites, THC-COOH and THC-
COOH-glu. The other major metabolite, 11-OH-THC, is also of interest in research studies 
[46]. Due to its relatively large window of detection, urine testing is useful for determining if 
a person has used drugs within the last few days. Additionally, urine testing can detect the 
metabolites of THC regardless of the route of consumption. Urine has been thoroughly 
researched as a matrix for drug testing and testing procedures are well-established. 
However, urine testing has some significant disadvantages, such as its ease of adulteration 
either through dilution or substitution, particularly due to privacy issues with collection. 
The large and varied window of detection observed can also pose problems when 
interpreting results, as the metabolites of THC may be found in the urine up to 12 days after 
a single oral dose [20] and even longer if the subject is a regular user. Although drug testing 
of any kind cannot itself confirm that an individual is impaired, urine testing is widely 
accepted as a means of identifying the risk of impairment.  
Due to the introduction of CBD-containing medicines such as Sativex, it has become of 
interest to detect CBD in urine. Generally, urine testing for cannabis targets the THC-COOH 
metabolite as it is present in much higher concentrations than the parent THC. Analysis of 
CBD in urine is relatively new, and so the parent compound is targeted due to lack of 
knowledge of the exact mechanism of its metabolism to CBD-7-oic acid. Commercial 
standards for this compound are not yet available, partly due to the difficulty in its 
synthesis. A 10-step synthesis has been outlined previously [47]. As need arises for the 
analysis of the CBD metabolite in urine, more effort will be put into developing a standard. 
Screening tests 
Immunoassay screening is often performed on urine samples either on-site or in a 
laboratory. Common types of tests include ELISA and CEDIA with cut-off concentrations 
typically ranging from 25 to 100 ng/mL. EMIT has also been used [38]. These immunoassays 
all target the metabolite THC-COOH, though they also have varying cross-reactivities with 
other cannabinoids. The cross-reactivity with CBD is generally quite low in these tests, and 
so they are unlikely to give a positive result if CBD is the sole cannabinoid present. 
Confirmatory tests 
Cannabinoids are mainly present in urine in their glucuronated forms. Alkaline or 
enzymatic hydrolysis of urine samples is performed to cleave glucosidic bonds, allowing for 
the free THC, THC-COOH and CBD to be analysed by GC–MS techniques following 
derivatisation. Alkaline hydrolysis is more effective for de-conjugating THC-COOH-glu 
[34], while enzyme hydrolysis using E. coli beta-glucuronidase is preferred for releasing free 
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THC [48]. Enzyme hydrolysis using beta-glucuronidase isolated from red abalone resulted 
in a 250-fold higher concentration of CBD compared with alkaline hydrolysis or no 
hydrolysis [34]. Tandem alkaline/enzyme hydrolysis has also been performed when 
analysing THC and THC-COOH simultaneously [49]. This may be useful for future 
simultaneous analyses of CBD and CBD-7-oic acid in urine. To avoid uncertainties due to 
hydrolysis variability, glucuronide conjugated metabolites can be analysed directly with the 
use of LC–MS/MS [50]. Following hydrolysis, sample clean-up procedures utilising either 
SPE or LLE are performed. 
Derivatisation before GC–MS analysis is typically performed using BSTFA with 1% 
trimethylsilyl chloride (TMCS) giving trimethylsilylated derivatives [34, 49, 51]. A 
combination of (pentafluoropropionic anhydride) PFPA and (pentafluoropropanol) PFPOH 
has also been used to produce acylated derivatives [52]. An LOQ of 0.9 ng/mL was achieved 
for THC-COOH using GC–MS following enzyme hydrolysis and derivatisation. CBD and 
THC were found to be quantifiable down to 3.4 and 3.9 ng/mL, respectively [51]. 
An LOQ of 2 ng/mL for THC and THC-COOH was achieved using an LC-MS method after 
alkaline hydrolysis [46]. Use of LC with tandem MS following enzyme hydrolysis achieved 
an LOQ of 1 ng/mL for CBD, THC and THC-COOH [53]. Without hydrolysis, an LC–MS/MS 
method was able to simultaneously quantify THC-glu at 0.5 ng/mL and THC-COOH-glu at 
5 ng/mL; free THC-COOH and CBD were also quantified down to 1 ng/mL and THC down 
to 2 ng/mL [50]. Also using LC–MS/MS without any hydrolysis, Wei et al. [54] recently 
achieved very low LOQ values at 0.008 ng/mL for THC and CBN, 0.012 ng/mL for CBD, 
0.018 ng/mL for THC-COOH and 0.028 ng/mL for 11-OH-THC. 
Drug metabolite concentrations in urine are heavily dependent on hydration and may be 
diluted with increased urine output. Therefore, measured concentrations of any drug 
compound or metabolite are routinely normalised using creatinine concentrations, which are 
relatively stable in urine. Determining concentrations of THC-COOH as ng/mg creatinine 
allows for comparisons between samples and can help identify re-use based on THC-
COOH/creatinine ratios in sequential samples from an individual [55-57]. These could 
potentially be applied to CBD or CBD-7-oic acid concentrations found in urine. 
Oral fluid  
Oral fluid testing is advantageous for determining recent use of cannabis since the target 
analyte is the parent THC compound. THC is deposited in the oral cavity directly from 
smoking and is only detectable for a few hours. Following administration of a dose of 
Sativex containing 5.4 mg THC and 5.0 mg CBD, Lee et al. [58] found oral fluid 
concentrations of THC and CBD both peaked at well over 1000 ng/mL. Both cannabinoids 
remained at detectable levels (1.0–60.0 ng/mL THC, 0.5–67.8 ng/mL CBD) up to 10.5 hr after 
 11 
dosage [58]. Following heavy dosage patterns, THC concentrations peaked between 5356 
and 15,468 ng/mL and CBD peaked over the range of 3826 to 17,233 ng/mL [37]. The average 
THC/CBD ratio was 1.10 (%RSD 19.9), consistent with the composition of the Sativex spray. 
CBN was also detected (2.08–593 ng/mL) in all Sativex positive samples with peak 
concentrations correlating with peak THC and CBD concentrations. CBN is likely present in 
the formulation as a result of the extraction process. Although the blood concentrations of 
THC are much lower in Sativex patients, and perhaps do not result in significant 
impairment, oral fluid concentrations may still be quite high due to these initial deposits left 
in the mouth by the spray. This could lead to difficulties interpreting positive results when 
the purpose of testing is to determine the likelihood of impairment. 
Screening tests 
There are a vast number of point-of-care screening devices available for the detection of 
THC in oral fluid. Some of the devices that have been evaluated in peer-reviewed journals 
within the last few years include the Cozart® DDS, Dräger DrugTest® 5000, RapidSTAT®, 
DrugWipe® 5+, OraLab® 6, OrAlert™ and OraTect® III (Table 1) [59-63]. All the currently 
available devices target the parent compound THC, though many have recorded cross-
reactivity with 11-OH-THC and THC-COOH. No current screening methods detect CBD. A 
laboratory based ELISA screening kit from Immunalysis has also been used for the detection 
of THC in oral fluid [64, 65]. This test kit targets THC, however it has also showed cross-
reactivity with other cannabinoids, including CBD at 50% [64]. 
Table 1: Oral fluid screening tests for cannabis 




Cozart® DDS Alere 31 [59, 61] 
Dräger DrugTest® 5000 Dräger Safety 5 [59-63] 
RapidSTAT® Mavand 15 [59-62] 
DrugWipe® 5+ Securetec 30 [59-62] 
OraLab® 6 Varian 50 [59] 
OrAlert™ Innovacon 100 [59] 
OraTect® III Branan 40 [59] 
ELISA kit Immunalysis 4 [64, 65] 
The DrugWipe® II Twin and Cozart® DDS devices were used to conduct screening tests in 
participants receiving Sativex treatment as an aid to withdrawal. The Cozart® DDS device 
successfully detected THC in all the participants who were receiving the Sativex treatment, 
with confirmed oral fluid concentrations all >52.4 ng/mL [37]. The DrugWipe® device 
however, had a very low sensitivity to the Sativex spray, as negatively screened samples 
were found to contain 52–11,624 ng/mL THC [37]. Samples that screened positive were in 
the range of 166–15,468 ng/mL THC [37]. 
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Confirmatory tests 
Due to the viscosity of oral fluid, many collection devices dilute oral fluid at the point of 
collection so lower limits of detection are necessary to accurately quantify cannabinoids in 
the neat oral fluid. Additionally, the oral fluid matrix and some commercial collection 
buffers can cause ion suppression issues in LC analyses; however, this is largely overcome 
by using a sample clean-up method. A number of methods to simultaneously analyse 
multiple cannabinoids including both THC and CBD in oral fluid have recently been 
published. These methods utilise GC–MS [66-68], 2D–GC–MS [69] and LC–MS/MS [37, 68, 
70-72]. Solid phase extraction is the most common form of sample preparation, however 
modified versions including SPME (solid phase micro-extraction) [68] and MEPS (micro-
extraction by packed sorbent) [72] have also been used, as well as liquid-liquid extraction 
[37, 71]. 
Expectorated oral fluid is sometimes used, however oral fluid is often collected using a 
collection device such as the Quantisal [69-71] and Cozart DDS [37] collectors. Both 
collectors dilute the collected oral fluid 1:3 with a stabilising buffer. Volumes of oral fluid or 
oral fluid/buffer mixes used for analysis range from 125–1000 µL. LOQs of THC and CBD 
were 0.5–2 and 0.9–2 ng/mL, respectively, when analysed by GC–MS [66-68]. Using LC–
MS/MS, LOQs were 0.25–1 ng/mL for THC and 0.3–2 ng/mL for CBD [37, 71-73]. Milman et 
al. achieved a 0.5 ng/mL LOQ for both THC and CBD collected by the Quantisal device and 
analysed using 2D–GC–MS [69]. Similarly, Concheiro et al. achieved the same quantification 
limits using micro-flow LC–MS/MS [70]. Milman et al. also successfully validated their 
method for 500 µL neat, expectorated oral fluid with an LOQ of 0.25 ng/mL for both THC 
and CBD [74]. 
Cannabinoids CBN and tetrahydrocannabinolic acid A (THCA-A) and THC metabolites, 11-
OH-THC and THC-COOH are also often targeted in simultaneous cannabinoid 
quantification methods. It has been suggested that the detection of 11-OH-THC and THC-
COOH in oral fluid is indicative of active cannabis smoking, rather than passive exposure, 
since these metabolites are not present in cannabis smoke [64]. THC-COOH is present in oral 
fluid at only pictogram per millilitre concentrations, hence methods must be suitably 
sensitive.  It may be worth investigating whether any THC precursor, THCA-A remains in 
the cannabis extracts used to produce Sativex. Smoking cannabis results in only partial 
decarboxylation of THCA-A [75]. Fabritius et al. [71] found relatively high concentrations of 
THCA-A in oral fluid after the smoking of cannabis joints. Peak THCA-A concentrations of 
44–2031 ng/mL correlated with peak THC concentrations in the oral fluid shortly after 
commencing smoking indicating that it is also deposited into the oral cavity [71]. If Sativex 
contains a very small amount of THCA-A or none at all, elevated levels found in the oral 
fluid could indicate use of other cannabis products. 
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Hair 
Cannabinoids may be incorporated into hair by passive diffusion from the bloodstream 
during growth of the hair fibre, secretions from sweat and sebaceous glands, or by 
deposition of external contaminants [76]. This matrix is most useful for estimating the 
approximate time and duration of past events as the growth rate of the hair and distance of 
the hair section from the scalp can provide this type of information. Specific time intervals 
cannot be determined due to the varied growth rates between individuals [77]. Increases and 
decreases in the concentration of cannabinoids found in different segments of hair can also 
indicate patterns of use over time. This makes hair analysis useful in the contexts of 
rehabilitation and child exposure to cannabis, among others [78]. Hair testing has a long 
window of detection and a user would have to abstain for three months to produce a 
negative sample for a typical 3 cm hair sample [77]. Though problematic if used alone, hair 
testing may be complementary to other matrices as it can give an indication as to whether a 
positive blood, urine or oral fluid test is due to a single use or regular use of cannabis.  
Methods for the analysis of cannabinoids in hair often include CBD, and CBN as well as 
THC. Therefore, these methods could be directly applied to Sativex patients to monitor 
medication compliance. An issue described with hair analysis is the difficulty in 
distinguishing between cannabinoids that are within the hair and external contamination 
[79]. This has been mostly overcome by performing confirmatory analysis of the THC 
metabolite, THC-COOH. However, the metabolite is incorporated into hair at smaller 
concentrations compared with the parent THC, so it may not be detected if only small doses 
were used [77]. According to the Society of Hair Testing, the recommended cut-off for the 
screening of cannabinoids in hair is 100 pg/mg and the cut-offs for confirmatory analyses are 
50 pg/mg for THC and 0.2 pg/mg for THC-COOH [80]. 
Hair collection is simple and non-invasive. Strands are collected from the back of the head 
(vertex posterior) either by pulling, or cutting as close to the scalp as possible [76, 81, 82]. 
Hair segments of 3 cm in length are most commonly used though different sectioning 
patterns are used for different testing purposes [77]. Hair samples are much more stable 
than other matrices and can be stored at ambient temperatures until analysis [76, 82]. In 
order to minimise the detection of external contaminants, hair samples are decontaminated 
by sequential washes, sometimes first with water [76, 78], followed by two or three washes 
with a solvent such as methylene chloride [82, 83], dichloromethane [76, 78, 84] or 
isopropanol [81]. The final wash is typically retained for analysis in order to confirm no 
external cannabinoids remain in the samples. Strands are then either cut into segments <1–2 
mm [78, 81, 84] or pulverised using a ball mill [82, 85]. Samples of 10 to 100 mg are then 
subjected to alkaline hydrolysis to destroy the hair and release the analytes, most commonly 
performed using 1 mL of 1 M sodium hydroxide and incubated for 10–30 min at 90–100° C 
[76, 78, 81-84]. Analytes are extracted after cooling, often by liquid-liquid extraction with a 
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mixture of n-hexane and ethyl acetate [78, 81-84]. Solid phase extraction has also been used 
[86]. If THC-COOH is an analyte of interest, acetic acid is added to reduce the pH to allow 
for the extraction of the acidic metabolite [78, 83, 86].  
Screening tests  
Cannabinoids are present in hair in much lower concentrations than urine, blood, and oral 
fluid, so sensitive instrumentation is required for its analysis and GC–MS is commonly used 
for this purpose. Cirimele et al. [82] recommended using GC–MS in SIM mode to rapidly 
screen for THC, CBD and CBN and then confirm results by analysing for THC-COOH. The 
limits of detection achieved were 0.1 ng/mg for THC, 0.02 ng/mg for CBD and 0.01 ng/mg 
for CBN. Screening using the rapid GC–MS method detected cannabinoids in real samples at 
ranges of 0.1–0.29 ng/mg THC, 0.03–3.00 ng/mg CBD and 0.01–1.07 ng/mg CBN. Huestis et 
al. [86] adapted an ELISA kit designed for use with blood and urine samples to analyse hair 
samples. The immunoassay achieved an LOD of 2 pg/mg THC, though they ultimately used 
a cut-off of 5 pg/mg for screening and found cross-reactivity of 340% THC-COOH, 51% CBN 
but only 0.1% CBD when compared with THC [86]. 
Confirmatory tests 
GC–MS methods have been most common for the analysis of cannabinoids in hair, however, 
due to the low concentrations of THC-COOH found, more sensitive instrumentations are 
now preferred. These typically include tandem MS systems coupled to either GC [76, 86] or 
LC [78, 84]. 
Samples are generally derivatised before analysis by GC–MS. Derivatisation using 
PFPA/PFPOH allowed for the detection of THC-COOH in collected hair samples at 0.02–0.39 
ng/mg hair by negative chemical ionisation GC–MS [83]. Another method by Kim et al. 
involving derivatisation using N-methyl-N-(trimethylsilyl)trifluoroacetamide/trimethylsilyl 
chloride/N-(trimethylsilyl)imidazole (MSTFA/TMCS/TMSI) at 60 °C for 15 min achieved an 
LOQ of 0.05 ng/mg hair for THC, CBD and CBN [81]. A method utilising GC–MS/MS with 
an LOQ of 1 pg/mg for THC and 0.1 pg/mg for THC-COOH enabled Huestis et al. [86] to 
detect THC down to 3.4 pg/mg and THC-COOH at 0.10–7.3 pg/mg in real hair samples. 
Emidio et al. [76] achieved LOQ values of 62 pg/mg THC, 12 pg/mg CBD and 30 pg/mg CBN 
using headspace SPME–GC–MS/MS. This technique efficiently combines analyte extraction 
and pre-concentration into a single step. LC–MS/MS methods using LLE have been able to 
quantify THC-COOH at 0.2 pg/mg [78] and THC, CBD and CBN at 3.9, 18 and 5.3 pg/mg 
[84]. Montesano et al. [87] were able to quantify THC-COOH at 0.1 pg/mg using pressurised 
liquid extraction followed by SPE before analysis by LC–MS/MS. LOQ values of 1.0 pg/mg 
for THC and 2.0 pg/mg for CBD and CBN were achieved by this method. 
Using GC–MS, Kim et al. detected THC, CBD and CBN in samples collected from cannabis 
users at an average of 0.14, 0.04 and 0.36 ng/mg, respectively [81]. CBN was the most 
detected cannabinoid, THC the least, possibly due to pyrolitic degradation of THC during 
 15 
smoking [81].  Similarly, Emidio et al. found hair samples more commonly contained CBN 
than THC with an average CBN concentration of 96 pg/mg compared with an average THC 
concentration of 56 pg/mg [76]. Analyses of hair samples by LC–MS/MS however, have not 
shown this trend. Salamone et al. [84] found THC, CBD and CBN in hair in ranges of 50–553 
pg/mg, 18–1862 pg/mg and 31–205 pg/mg, respectively. Dulaurent et al. [78] detected a high 
amount of THC (1122 pg/mg) and no CBN in a hair sample. 
 
Other matrices 
Alternative matrices for the non-invasive detection of cannabis include sweat and exhaled 
air. Sweat patches that are placed on the body for hours or even days collect excreted sweat 
that can be analysed for the presence of drugs [88]. This is most suited to patient care and 
monitoring purposes, due to the timeframe required for sample collection. A faster 
screening test, the DrugWipe “K” is an immunoassay that can detect a number of illicit 
drugs including THC after being wiped across the forehead a few times [89]. The parent 
compounds are the analytes of interest in sweat testing so CBD could also be targeted in 
confirmatory analyses. However, passive contamination may be an issue and there is a 1–12 
hr delay between drug administration and excretion into sweat [90]. Kintz et al. [90] found 
THC in the range of 4 to 152 ng/pad in 16 sweat samples collected using cosmetic pads 
spiked with water/isopropanol (1:1). Actual concentrations in sweat could not be 
determined since the volume of sweat collected is unknown. Metabolites 11-OH-THC and 
THC-COOH were not detected. SAMHSA guidelines include cut-off values of 4 ng/patch 
and 1 ng/patch for screening and confirmatory analysis, respectively, for the detection of 
parent THC in sweat patches [91]. Saito et al. [92] achieved an LOQ of 0.4 ng/patch for THC 
in sweat using PharmChek patches and GC–NCI–MS. Huestis et al. [93] found positive 
sweat patch results in daily cannabis users for at least a week after cessation of use, however 
THC was not detected after oral ingestion of up to 14.8 mg THC. 
Skoglund et al. [94] found exhaled breath had a narrower window of detection than plasma 
or urine, making it useful for indicating recent use, however it was less sensitive than 
plasma analysis. Stephanson et al. [95] achieved an LOQ of 6 pg/filter THC in exhaled breath 
collected using a SensAbues device and analysed by LC–MS/MS. THC was successfully 
measured using this method in eight real samples at 27–557 pg/filter [95]. 
The LOQ values for the confirmatory analysis of cannabinoids in the matrices discussed 
above are summarized in Table 2. 
Table 2: Summary of LOQ values for the detection of cannabinoids in biological matrices. 
Matrix Analysis method LOQ* (analyte) Ref. 
Plasma GC–MS 0.080 (THC); 0.95 (CBD); 3.9 (CBN); 0.5 [38] 
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(11-OH-THC); 0.88 (THC-COOH) 
GC–MS 0.1 (THC, CBD, 11-OH-THC) [26] 





LC–MS/MS 2 (THC); 3 (CBD, 11-OH-THC, THC-
COOH) 
[44] 
LC–MS/MS 1.0 (THC, CBD, CBN, 11-OH-THC, THC-
COOH); 0.5 (THC-glu); 5.0 (THC-COOH-
glu) 
[45] 
Urine GC–MS 3.4 (THC); 3.9 (CBD); 0.9 (THC-COOH) [51] 
LC–MS 2 (THC, THC-COOH) [46] 
LC–MS/MS 1 (THC, CBD, THC-COOH) [53] 
LC–MS/MS 0.5 (THC-glu); 5 (THC-COOH-glu); 1 
(CBD, THC-COOH); 2 (THC) 
[50] 
LC–MS/MS 0.008 (THC, CBN); 0.012 (CBD); 0.018 
(THC-COOH); 0.028 (11-OH-THC) 
[54] 
Oral fluid  
 
GC–MS 0.5 (THC, CBN); 1 (CBD, THCA-A) [66] 
GC–MS 1.9 (THC); 0.9 (CBD); 4.8 (THC-COOH); 
12.7 (11-OH-THC); 5.6 (CBN) 
[67] 
SPME–GC–MS 2 (THC, CBD, CBN) [68] 
LC–MS/MS 1 (THC); 2 (CBD, CBN) [37] 
LC–MS/MS 0.5 (THC, CBD, CBN, 11-OH-THC, 
THCA-A); 0.08 (THC-COOH) 
[71] 
LC–MS/MS 0.25 (THC); 0.3 (CBD, CBN); 0.02 (THC-
COOH); 0.4 (11-OH-THC) 
[72] 
LC–MS/MS 1 (THC) [73] 
2D–GC–MS 0.5 (THC, CBD) [69] 
Micro-flow LC–MS/MS 0.5 (THC, CBD) [70] 
LC–MS/MS 0.25 (THC, CBD) [74] 
Hair GC–MS 50 pg/mg (THC, CBD, CBN) [81] 
GC–MS/MS 1 pg/mg (THC); 0.1 pg/mg (THC-COOH) [86] 
Headspace SPME–GC–
MS/MS 
62 pg/mg (THC); 12 pg/mg (CBD); 30 
pg/mg (CBN) 
[76] 
LC–MS/MS 0.2 pg/mg (THC-COOH); 50 pg/mg 
(THC, CBD, CBN) 
[78] 
LC–MS/MS 3.9 pg/mg (THC); 18 pg/mg (CBD); 5.3 
pg/mg (CBN) 
[84] 
 LC–MS/MS 0.1 pg/mg (THC-COOH); 1.0 pg/mg 
(THC); 2.0 pg/mg (CBD, CBN) 
[87] 




LC–MS/MS 6 pg/filter (THC) [95] 
*LOQ measurements given in ng/mL unless otherwise stated. 
Correlation between matrices 
Urine has a large window of detection since THC-COOH is eliminated slowly and variably 
over time. Blood analysis generally targets the parent THC to give a shorter window of 
detection and hence a better indication of recent use as THC levels decline to low, ‘baseline’ 
levels within a few hours of use. However, THC may still be detectable in blood at low 
levels for days or even weeks in chronic heavy users. Odell et al. [96] measured an average of 
1.9 ng/mL THC in whole blood 148 hr after last use and Bergamaschi et al. [40] detected THC 
(≥0.3 ng/mL) in blood samples up to 30 days after last use. Major metabolite THC-COOH, 
also remains detectable in the urine of chronic users for prolonged periods. Peak 
concentrations of THC and CBD in plasma following cannabinoid administration via oral 
capsules was reached at ~1 hr, while the peak concentration of THC-COOH was reached at 
~2 hr [38]. THC-COOH levels in blood were found to peak 1.2–7.5 hr after Sativex 
administration [27]. These provide some correlation with the detection of urinary THC-
COOH, however lower concentrations of the metabolite are observed in blood. 
Correlation between oral fluid and plasma varies, depending on route of exposure. Huestis 
and Cone [97] found that after the initial deposits from smoking had been depleted, the 
concentration of THC in oral fluid was well correlated to plasma concentrations until 4 
hours after use. However, Kauert et al. [98] found that the similar elimination rates of THC 
from oral fluid and plasma are merely coincidental. Toennes et al. [99] and Laloup et al. [100] 
obtained data indicating that the detection of THC in oral fluid is a good predictor for THC 
also being found in plasma and therefore the subject being under the influence of cannabis. 
Sativex administration has been shown to result in much lower plasma concentrations 
compared with smoking cannabis, and hence these correlations will not be useful since high 
oral fluid concentrations will not equate to high plasma concentrations or a high risk of 
impairment. Conversely, ingested cannabis (brownies or capsules) result in lower oral fluid 
concentrations relative to plasma, so an individual may be influenced while no THC is 
detectable in the saliva. Niedbala et al. [101] found mean peak concentrations of 23.3 and 
25.3 ng/mL of THC in oral fluid collected from the left and right sides of the mouth, 
respectively, after subjects smoked a single cigarette containing 20–25 mg of THC. 
Comparatively, the mean peak concentrations detected following the ingestion of brownies 
containing the same amount of THC was only 3.4 and 4.8 ng/mL in oral fluid collected from 
the left and right sides of the mouth, respectively. Additionally, Milman et al. [74] noted that 
orally administered capsules of Marinol® (synthetic THC) are unlikely to result in detectable 
concentrations of THC appearing in the oral fluid.  
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Skoglund et al. [94] found good correlation between exhaled breath and plasma with 
positive breath tests for THC concurring with positive plasma results and negative breath 
tests corresponding to negative or low concentrations of THC in plasma. Their results 
indicated that exhaled breath had a shorter window of detection than plasma. 
The suitability of a biological matrix depends on the purpose of testing and the available 
facilities. Table 3 summarizes the major advantages and disadvantages of using blood, urine, 
oral fluid and hair matrices for cannabinoid testing. 
Table 3: Summary of the benefits and drawbacks of the major testing matrices. 
Matrix Advantages Disadvantages 
Plasma/whole blood [27, 
39] 
Short window of detection for 
parent THC is useful for 
determining recent use and 
possible impairment. 
Relatively high concentrations 
of THC-COOH allow for easier 
detection. 
Specialist equipment and 
personnel required for sample 
collection. 
Highly sensitive methods 
required to detect parent THC. 
Urine [20, 49] Longer window of detection is 
useful for long-term drug 
monitoring. 
Cannabinoid concentrations are 
unaffected by route of 
exposure. 
Simple to collect. 
Longer window of detection 
can be problematic when 
interpreting a positive result. 
Privacy concerns surrounding 
sample collection. 
Prone to adulteration practices. 
Oral fluid [102] Shortest window of detection 
for parent THC. 
Simple, non-invasive collection 
methods. 
Large variations in cannabinoid 
concentrations depending on 
route of exposure. 
Hair [77-79] Longest window of detection is 
useful for determining historic 
use or exposure. 
Simple, non-invasive collection.  
Helpful as a complementary 
testing matrix to confirm 
positive results from other 
tests. 
 
Difficulties in distinguishing 
between active use and passive 
exposure. 
Varied growth rates prevent 
determination of specific time 
intervals. 
Sensitive detection methods 
required for the low picogram 
concentrations present. 
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When attempting to determine recent use or risk of impairment, the detection of parent THC 
is most appropriate, either in blood or oral fluid. Due to its short half-life THC is generally 
only detectable for a few hours in these matrices for occasional users. The window of 
detection in blood and oral fluid is extended when analysing for the metabolites, as these 
appear later and persist for longer. However, recent research shows the length of time the 
various cannabinoids and their metabolites remain is dependent on a number of factors and 
is highly variable between individuals [102]. Consequently, while a positive blood or oral 
fluid result may be indicative of recent use, determining a specific time of last use is not 
currently feasible. Detecting multiple cannabinoids and using oral fluid/plasma ratios are 
promising ways to indicate recent use, however more research is required before these can 
be used to determine more accurate windows of detection [103, 104]. 
Analytical pitfalls 
Analysis of cannabinoids in biological matrices has been subject to difficulties due to the 
instability of the compounds when stored in these matrices. Degradation of cannabinoids in 
urine and blood is often the result of oxidative processes with pH and temperature playing 
major roles [56]. Even freezing cannot halt degradation; a 26% decrease in THC 
concentration was observed in urine stored at –70 °C in silanised glass after five months [53]. 
Nevertheless, freezing of urine and blood or plasma samples is preferred as higher losses are 
observed in refrigerated samples and even more so in samples stored at room temperature. 
Desrosiers et al. [105] recommended analysing urine within three months if THC-COOH-glu 
is of interest since it undergoes deconjugation over time, and thus increasing THC-COOH 
concentrations while the glucuronide decreases. Similarly, Scheidweiler et al. [106] found 
THC-COOH-glu and 11-OH-THC concentrations in plasma fell whilst THC-COOH 
concentrations increased over one week at room temperature. 
Oral fluid is commonly collected using commercial kits that dilute the sample with a 
stabilising buffer at the point of collection. This improves cannabinoid stability compared 
with neat oral fluid samples, though refrigerated storage and analysis within a few weeks is 
still recommended for samples collected using the Quantisal, StatSure and Oral-Eze devices 
[107, 108]. THC in expectorated oral fluid diluted with phosphate buffer at pH ~6 was stable 
for three weeks when refrigerated, while samples diluted with Cozart DDS buffer solution 
was stable for at least four weeks at room temperature [109]. 
In addition to losses through degradation, THC is known to be highly lipophilic, commonly 
resulting in adsorptive losses to precipitants and surfaces during storage or sample 
preparation [109, 110]. CBD is also lipophilic [110] and is likely subject to similar effects. The 
lipophilicity of THC coupled with the high polarity of THC-COOH has been problematic for 
developing extraction procedures capable of extracting both analytes efficiently in a single 
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sample [44]. These attributes must be taken into consideration when collecting, storing and 
analysing samples for cannabinoids. Bergamaschi et al. [40] processed blood samples in an 
ice bath to minimise adsorption of cannabinoids onto precipitant materials. Jagadeo et al. 
[44] added acetonitrile to blood samples to desorb any cannabinoids from the container 
walls during their sample preparation. Addition of a non-ionic surfactant has also been 
shown to reduce the degree of adsorption of THC to polypropylene surfaces in neat oral 
fluid samples [109]. 
THC and CBD give identical fragmentation patterns when analysed by LC-MS/MS with ESI 
in positive ionisation mode. Broecker et al. [111] determined that this phenomenon is due to 
an acid-catalysed equilibrium between THC and CBD that occurs specifically under positive 
ESI conditions. Therefore, it should be noted that in any +ESI–LC–MS/MS analysis of THC or 
CBD (or both), THC and CBD must be chromatographically separated as they cannot be 
distinguished by MS or MS/MS data alone. 
Sativex treatment compliance 
Most illicit cannabis contains high amounts of THC and is low in CBD [3, 4]. Observing 
similar concentrations of THC and CBD in any biological matrix is a good indication of 
Sativex treatment since the formulation contains an almost equal amount of the two. 
However, this current distinction may become irrelevant in the future as cannabis plants 
containing higher CBD content increase in popularity, and with the emergence of e-
cigarettes containing high levels of CBD with respect to THC [102, 112]. Sativex doses may 
also mask concurrent illicit use [37]. Presence of THC-COOH in oral fluid has been used to 
indicate active use of cannabis rather than passive exposure. A marker for distinguishing 
Sativex treatment from illicit cannabis use may be the precursor, THCA-A. THCA-A was 
found in the oral fluid of cannabis smokers indicating it is only partially decarboxylated 
during smoking [71]. The method of manufacturing Sativex should result in no or very low 
amounts of THCA-A present in the formulations, so detecting this may indicate illicit use. 
Plasma 11-OH-THC/THC ratios were found to be higher after either Sativex administration 
or oral dosage with THC capsules (mean peak ratios of 1.1–2.1) than following cannabis 
smoking (0.0–0.5) [27]. Therefore elevated 11-OH-THC levels compared with THC may be 
an indicator of medicinal cannabis use, though not Sativex specifically. 
For long term monitoring of treatment compliance, hair testing may be appropriate. Hair 
testing is more expensive per sample, but it has the potential to give information over a 
much larger time frame and replace multiple blood or urine samples, reducing costs in the 
long term [77]. 
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Future perspective 
Increasingly, studies are including the analysis of CBD along with THC and its metabolites 
in biological matrices. Further research into CBD and its metabolites is necessary, however 
CBD-7-oic acid is currently lacking in commercial supply. Once this metabolite becomes 
available, additional pharmacokinetic studies are inevitable and will help identify how best 
to analyse each matrix for evidence of CBD intake. Accurate detection and quantification of 
CBD, THC and its metabolites will be useful for identifying Sativex use, however 
distinguishing this from concurrent use of recreational cannabis continues to be challenging. 
More research into potential markers for either Sativex or recreational cannabis will 
hopefully result in a reliable means to determine the source of cannabinoids present in a 
sample.  
Blood and urine remain the principal tools used for monitoring Sativex use. Oral fluid 
testing continues to be investigated and may be the preferred testing matrix if screening 
sensitivity and collection device reliability are significantly improved. Hair analysis also has 
its benefits, however, continued efforts in distinguishing internal exposure from external 
contamination are essential. Though still in its infancy, exhaled air is a promising matrix for 
future testing, particularly due to the non-invasiveness of breath testing. 
GC–MS is well established as a confirmatory testing tool for the quantification of 
cannabinoids in biological matrices. Although GC–MS/MS and 2D–GC–MS techniques have 
improved on the standard GC–MS methods, LC–MS methods, in particular LC–MS/MS, has 
caught up in terms of sensitivity and is set to overtake GC–MS. LC–MS is also becoming 
increasingly popular as a screening tool and may in future replace immunoassay-based 
testing for cannabinoids following Sativex administration. 
Executive summary 
Background 
- Quantitation of CBD and its metabolites in biological matrices is essential to monitoring 
Sativex administration. 
Future Perspective 
- Identification of markers that can distinguish between Sativex use and recreational 
cannabis use will be useful for determining concurrent cannabis use with Sativex 
administration. 
- LC–MS continues to be increasingly popular for both screening and confirmatory 
analyses for cannabinoids in biological matrices and is an important tool for the 
monitoring of Sativex use. 
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